BioLineRx (ADR) (BLRX)
Builds oncology assets around APHEXDA royalties and GLIX1 clinical development.
Something off on this page? Send us feedback.
Develops oncology and rare-disease therapies, combining APHEXDA royalties and partner milestones with clinical development of GLIX1 and retained solid-tumor rights to motixafortide. Its partnership-led model centers on licensing and development rather than direct U.S. commercialization.
Develops oncology and rare-disease therapies through a partnership-led asset-development model. Its portfolio combines royalty-bearing rights to APHEXDA, an approved stem-cell-mobilization treatment, with GLIX1, an oral DNA-damage-response candidate for glioblastoma and other cancers being developed through Tetragon Biosciences.
Earns royalties and may receive milestones when partners commercialize APHEXDA outside Asia and in Asian markets, while managing and funding GLIX1's clinical development in Israel. It also retains non-Asian solid-tumor rights to motixafortide and supports an investigator-led pancreatic-cancer trial.
Depends on partner execution and market use of APHEXDA for royalty revenue. GLIX1 remains in first-in-human dose escalation, and the small organization is concentrated in Israel.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $13.1M · Total debt $7.9M · Total assets $33.5M · Shareholders' equity $13.8M
- Revenue
- $299.0K
- Operating income
- −$3.6M
- Net income
- −$3.1M
No dividends on record.
| Institutions13 holders · as of Mar 31, 2026 | 0.45% | 19.6K ADS | |
| Otherremainder | 99.55% | 4.33M ADS |
4.35M ADS as of Aug 25, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
XTX Topco LtdInstitution | 0.25% | 10,941 ADS | 13Fas of Mar 31, 2026 |
Rhumbline AdvisersInstitution | 0.05% | 2,353 ADS | 13Fas of Mar 31, 2026 |
BNP Paribas Arbitrage, SNCInstitution | 0.04% | 1,800 ADS | 13Fas of Mar 31, 2026 |
Wells Fargo & Company/MNInstitution | 0.04% | 1,750 ADS | 13Fas of Mar 31, 2026 |
Citigroup IncInstitution | 0.04% | 1,728 ADS | 13Fas of Mar 31, 2026 |
| See all 23 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Sanofi (ADR)
Branded Mozobil anchors APHEXDA's stem-cell-mobilization market.
- Teva (ADR)
Low-cost generic plerixafor directly substitutes for APHEXDA.
- Exicure
Burixafor is an emerging CXCR4 mobilizer for multiple myeloma.
- Novocure
Optune provides an established glioblastoma treatment alternative.
- Kazia Therapeutics (ADR)
Paxalisib targets the same glioblastoma patient population.
- CNS Pharmaceuticals
Berubicin remains a modest recurrent-glioblastoma drug contender.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioLineRx (ADR) | $2.66 | −3.62% | $11.9M | — | — | 8.7 | −3.3% |
| Sanofi (ADR) | $44.57 | +0.24% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Teva (ADR) | $37.48 | +0.03% | $43.66B | 62.5 | 13.3 | 2.4 | −0.8% |
| Exicure | $1.36 | +3.40% | $8.2M | — | — | — | — |
| Novocure | $18.16 | +1.82% | $2.08B | — | — | 3.0 | +15.6% |
| Kazia Therapeutics (ADR) | $12.57 | −1.26% | $20.4M | — | — | 1,444.7 | — |
| CNS Pharmaceuticals | $6.04 | +2.51% | $8.8M | — | — | — | — |
| Median | 70.3 | 13.3 | 2.7 | +11.2% |